Recombinant Human Matrix Metalloproteinase-2 Impairs Cardiovascular β-Adrenergic Responses

Basic and Clinical Pharmacology and Toxicology

Volumn 112, Issue 2, 2013, Pages 103-109

  Ferraz, Karina C ^a   Sousa Santos, Ozélia ^b   Neto Neves, Evandro M ^b   Rizzi, Elen ^b   Muniz, Jaqueline J ^a   Gerlach, Raquel F ^b   Tanus Santos, Jose E ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; DOBUTAMINE; DOXYCYCLINE; GELATINASE A;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL TONE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; ENZYME ACTIVITY; HEMODYNAMICS; HUMAN; LAMB; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VASCULAR RESISTANCE;

ADRENERGIC BETA-1 RECEPTOR AGONISTS; ANIMALS; DOBUTAMINE; DOXYCYCLINE; HEMODYNAMICS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MATRIX METALLOPROTEINASE 2; RECEPTORS, ADRENERGIC, BETA-1; RECOMBINANT PROTEINS; SHEEP;

OVIS ARIES;

EID: 84872124323     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12001     Document Type: Article

References (38)

1. Castro MM, Rizzi E, Ceron CS, Guimaraes DA, Rodrigues GJ, Bendhack LM et al. Doxycycline ameliorates 2K-1C hypertension-induced vascular dysfunction in rats by attenuating oxidative stress and improving nitric oxide bioavailability. Nitric Oxide 2012;26:162-8.
2. Ceron CS, Rizzi E, Guimaraes DA, Martins-Oliveira A, Cau SB, Ramos J et al. Time course involvement of matrix metalloproteinases in the vascular alterations of renovascular hypertension. Matrix Biol 2012;31:261-70.
3. Marson BP, Poli de Figueiredo CE, Tanus-Santos JE. Imbalanced matrix metalloproteinases in cardiovascular complications of end-stage kidney disease: a potential pharmacological target. Basic Clin Pharmacol Toxicol 2012;110:409-15.
4. Neto-Neves EM, Dias-Junior CA, Uzuelli JA, Pereira RP, Spiller F, Czaikoski PG et al. Sildenafil improves the beneficial hemodynamic effects exerted by atorvastatin during acute pulmonary thromboembolism. Eur J Pharmacol 2011;670:554-60.
5. Castro MM, Rizzi E, Figueiredo-Lopes L, Fernandes K, Bendhack LM, Pitol DL et al. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 2008;198:320-31.
6. Castro MM, Rizzi E, Rodrigues GJ, Ceron CS, Bendhack LM, Gerlach RF et al. Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. Free Radic Biol Med 2009;46:1298-307.
7. Rizzi E, Castro MM, Prado CM, Silva CA, Fazan R Jr, Rossi MA et al. Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension. J Card Fail 2010;16:599-608.
8. Yamazaki T, Lee JD, Shimizu H, Uzui H, Ueda T. Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure. Eur J Heart Fail 2004;6:41-5.
9. Yasmin, McEniery CM, Wallace S, Dakham Z, Pulsalkar P, Maki-Petaja K et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005;25:372.
10. Ceron CS, Castro MM, Rizzi E, Montenegro MF, Fontana V, Salgado MC et al. Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. Br J Pharmacol 2010;160:77-87.
11. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore!. Curr Opin Cell Biol 2001;13:534-40.
12. Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 2007;47:211-42.
13. Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 1999;85:906-11.
14. Fernandez-Patron C, Stewart KG, Zhang Y, Koivunen E, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res 2000;87:670-6.
15. Martinez A, Oh HR, Unsworth EJ, Bregonzio C, Saavedra JM, Stetler-Stevenson WG et al. Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator. Biochem J 2004;383:413-8.
16. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002;106:1543-9.
17. Gao CQ, Sawicki G, Suarez-Pinzon WL, Csont T, Wozniak M, Ferdinandy P et al. Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction. Cardiovasc Res 2003;57:426-33.
18. Sawicki G, Leon H, Sawicka J, Sariahmetoglu M, Schulze CJ, Scott PG et al. Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2. Circulation 2005;112:544-52.
19. Sung MM, Schulz CG, Wang W, Sawicki G, Bautista-Lopez NL, Schulz R. Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-actinin in peroxynitrite mediated myocardial injury. J Mol Cell Cardiol 2007;43:429-36.
20. Ali MA, Cho WJ, Hudson B, Kassiri Z, Granzier H, Schulz R. Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury. Circulation 2010;122:2039-47.
21. Rietz A, Spiers J. The relationship between the MMP system, adrenoceptors and phosphoprotein phosphatases. Br J Pharmacol 2012;166:1225-43.
22. Rodrigues SF, Tran ED, Fortes ZB, Schmid-Schonbein GW. Matrix metalloproteinases cleave the beta2-adrenergic receptor in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2010;299:H25-35.
23. Wu KI, Schmid-Schonbein GW. Nuclear factor kappa B and matrix metalloproteinase induced receptor cleavage in the spontaneously hypertensive rat. Hypertension 2011;57:261-8.
24. Hakalahti AE, Vierimaa MM, Lilja MK, Kumpula EP, Tuusa JT, Petaja-Repo UE. Human beta1-adrenergic receptor is subject to constitutive and regulated N-terminal cleavage. J Biol Chem 2010;285:28850-61.
25. Goncalves AN, Meschiari CA, Stetler-Stevenson WG, Nonato MC, Alves CP, Espreafico EM et al. Expression of soluble and functional full-length human matrix metalloproteinase-2 in Escherichia coli. J Biotechnol 2012;157:20-4.
26. Palei AC, Sandrim VC, Amaral LM, Machado JS, Cavalli RC, Duarte G et al. Association between matrix metalloproteinase (MMP)-2 polymorphisms and MMP-2 levels in hypertensive disorders of pregnancy. Exp Mol Pathol 2012;92:217-21.
27. Yerebakan C, Klopsch C, Niefeldt S, Zeisig V, Vollmar B, Liebold A et al. Acute and chronic response of the right ventricle to surgically induced pressure and volume overload-an analysis of pressure-volume relations. Interact Cardiovasc Thorac Surg 2010;10:519-25.
28. Fortuna GM, Figueiredo-Lopes L, Dias-Junior CA, Gerlach RF, Tanus-Santos JE. A role for matrix metalloproteinase-9 in the hemodynamic changes following acute pulmonary embolism. Int J Cardiol 2007;114:22-7.
29. Neto-Neves EM, Dias-Junior CA, Rizzi E, Castro MM, Sonego F, Gerlach RF et al. Metalloproteinase inhibition protects against cardiomyocyte injury during experimental acute pulmonary thromboembolism. Crit Care Med 2011;39:349-56.
30. Sousa-Santos O, Neto-Neves EM, Ferraz KC, Ceron CS, Rizzi E, Gerlach RF et al. Antioxidant treatment protects against matrix metalloproteinase activation and cardiomyocyte injury during acute pulmonary thromboembolism. Naunyn Schmiedebergs Arch Pharmacol 2012;385:685-96.
31. Muniz JJ, Lacchini R, Belo VA, Nobre YT, Tucci S Jr, Martins AC et al. Circulating matrix metalloproteinases and their endogenous inhibitors in patients with erectile dysfunction. Int J Impot Res 2012;24:38-43.
32. Fontana V, Silva PS, Belo VA, Antonio RC, Ceron CS, Biagi C et al. Consistent alterations of circulating matrix metalloproteinases levels in untreated hypertensives and in spontaneously hypertensive rats: a relevant pharmacological target. Basic Clin Pharmacol Toxicol 2011;109:130-7.
33. Castro MM, Tanus-Santos JE, Gerlach RF. Matrix metalloproteinases: targets for doxycycline to prevent the vascular alterations of hypertension. Pharmacol Res 2011;64:567-72.
34. Fontana V, Silva PS, Gerlach RF, Tanus-Santos JE. Circulating matrix metalloproteinases and their inhibitors in hypertension. Clin Chim Acta 2012;413:656-62.
35. Altieri P, Brunelli C, Garibaldi S, Nicolino A, Ubaldi S, Spallarossa P et al. Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest 2003;33:648-56.
36. Cheung PY, Sawicki G, Wozniak M, Wang W, Radomski MW, Schulz R. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000;101:1833-9.
37. Wang GY, Bergman MR, Nguyen AP, Turcato S, Swigart PM, Rodrigo MC et al. Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility. Cardiovasc Res 2006;69:688-96.
38. Bergman MR, Teerlink JR, Mahimkar R, Li L, Zhu BQ, Nguyen A et al. Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol 2007;292:H1847-60.